Rasagiline mesylate API
CAS.NO:161735-79-1
structural formula:C13H17NO3S
EINECS.no:694-423-3
Other names:CS-289;R-(+)-Rasagiline mesylate;Agilect;TVP-1012;Rasagiline Mesylate
Test Method:HPLC/UV/GC-MS
MOQ & Package: 10g,100g,1kg,5kg,10kg,25kg etc
Customer's rights and interests:Over 10kg, you can enjoy the service of giving away free samples.
Certificate：FDA,ISO,COA, HPLC, MSDS,TDS etc
Lead Time: 1-3 days
Shipping: DHL,Germany DHL,Germany DPD,UPS,USPS,FedEx,EMS,By Air,By Sea,multimodal transport etc
Store & Shelf life; Cool & dry place; 36 months
Company advantages: there are self-built overseas warehouses and third-party overseas warehouses on all continents.
- Product Description
Xi'an Faithful BioTech Co., Ltd: Your Trusted Rasagiline mesylate API Manufacturer & Supplier
Rasagiline mesylate API powder is the second generation of irreversible selective B-type monoamine oxidase inhibitor, which is mainly used to treat idiopathic Parkinson's disease. It can inhibit the degradation of dopamine in the brain, thus helping to alleviate the related dyskinesia of patients with Parkinson's disease. The research shows that the R-(+)-Rasagiline mesylate Powder provided by Xi'an Faithful BioTech Co., Ltd can not only improve the myocardial function, but also reduce the myocardial ischemic injury, and has a certain therapeutic effect on cardiovascular diseases such as myocardial infarction. In addition, it can also lower blood pressure and improve vascular endothelial function, which has a positive effect on the prevention and treatment of hypertension and arteriosclerosis.
Rasagiline mesylate API Introduction
Rasagiline mesylate is an irreversible monoamine oxidase inhibitor. By selectively inhibiting monoamine oxidase, the decomposition of dopamine can be reduced, and the extracellular level of dopamine in the high striatum of the brain can be increased. The increased dopamine level can alleviate the symptoms of Parkinson's disease. Compared with the first generation monoamine oxidase inhibitors, rasagiline mesylate API powder has a 5-10 times stronger inhibitory effect, and it can also improve the patients whose efficacy declines after long-term application of dopa preparation. In addition, the metabolite of rasagiline is an inactive substance with little side effects. More importantly, TVP-1012 has neuroprotective effect, which is different from other anti-Parkinson's drugs. Combined therapy can optimize the therapeutic effect of levodopa, further effectively control symptoms and reduce exercise complications.
Specifications
Item | Specifications | Results |
Appearance | White or off-white crystalline powder | Complies |
Odor & Tasted | Characteristic | Complies |
a. IR-Spectrum b. HPLC | Matches with working standard | Complies |
Relative materia | Major ≤0.5% Total ≤1.0% | 0.37% 0.56% |
Water | < 0.3% | 0.12% |
Loss on drying | < 3.0% | 2.23% |
Ash | < 2.0% | 1.35% |
Residual solvents | Meets the requirements | Complies |
Heavy Metal | ≤10 ppm | 1.28ppm |
Pb | ≤1.0 ppm | 0.13ppm |
As | ≤1.0 ppm | Negative |
Hg | ≤0.1 ppm | Negative |
Cd | ≤0.1ppm | Negative |
Total Plate Count | ≤ 1000cfu/g | 13.31 cfu/g |
Total Yeast & Mold | ≤ 100cfu/g | 0.25 cfu/g |
E.Coli | ≤ 1cfu/g | Negative |
Salmonella | ≤ 1cfu/g | Negative |
Assay （HPLC） | 95%-100% | 98.25% |
| Conclusion | Conform with enterprise specification （USP 41）. |
Why Choose Us?
Choosing our R-(+)-Rasagiline mesylate raw material powder means that the purity of the product you choose is ≥98.5%, and the content of C12H13N·CH4O3S should be 98.5%~102.0% based on the dry product, the content of related substances is ≤1.0%, the sulfate content is ≤0.05%, the ignition residue is ≤0.2%, and the heavy metal content is ≤20ppm, all the quality indexes are in line with CP. We adopt advanced production technology, and mesylate rasagiline API Powder has passed the international authoritative certification such as FDA and EDQM, which meets the regulatory requirements of major global markets. Each batch shall be provided with a complete certificate of analysis (COA) to ensure that every link from raw material procurement to finished product delivery meets the requirements of good manufacturing practice (GMP). In addition, our products are more competitive in price and have obvious cost-benefit advantages, which is an ideal choice for your Parkinson's disease treatment program development.
Our email address is:sales8@faithfulbio.com, Welcome your letter.
Pharmacokinetics
The pharmacokinetic characteristics of rasagiline mesylate are mainly reflected in its absorption, distribution, metabolism and excretion. First of all, in terms of absorption, when it enters the body, it can be quickly absorbed by the gastrointestinal tract and enter the blood circulation system. Its high bioavailability means that the effective concentration of rasagiline mesylate in the body can be kept stable, thus ensuring the therapeutic effect. Secondly, in terms of distribution, rasagiline mesylate API can penetrate the blood-brain barrier, enter the central nervous system, and exert its therapeutic effect on the nervous system. At the same time, it can also be distributed in all tissues and organs of the whole body, which is of positive significance for the treatment of systemic diseases. Furthermore, in metabolism, it is mainly transformed into inactive metabolites through liver metabolism. This feature makes the half-life of rasagiline mesylate powder moderate in vivo, which not only ensures the durability of therapeutic effect, but also avoids the side effects caused by accumulation.
Quality Control:
R&D Results:
Packaging and Transportation:
After-Sales Service:
Qualification Certification:
Transaction Feedback:
Exhibition:
FAQ
Q1: What is rasagiline mesylate?
It is a potent, highly selective and irreversible MAO-B inhibitor, which has remarkable curative effect and good safety in the treatment of Parkinson's disease. Attention should be paid to liver function monitoring, drug interaction and drug use for special people, and the best therapeutic effect can be obtained by standardized use under the guidance of doctors.
Q2: What are the manifestations and treatment measures of rasagiline's excess?
In clinical research, it has not been reported excessively. Theoretically, drug overdose can significantly inhibit MAO-A and MAO-B, and may cause symptoms such as irritability, mild mania and hypertensive crisis. It has no special antidote. If overdose occurs, patients need to be closely monitored, and symptomatic treatment and supportive treatment should be carried out.
Q3: How to store in rasagiline?
Sealed, stored in a cool and dry place, not exceeding 30℃. The validity period is tentatively set at 24 months.
Contact us
Our rasagiline mesylate raw material powder has high purity and good quality, which is not only suitable for the development of Parkinson's disease treatment products, but also provides a reliable high-quality raw material solution for the research of other selective monoamine oxidase B inhibitor raw materials. If you need it, please leave a message:sales8@faithfulbio.com .
